■ General Information

Applications

- Immunohistochemistry
  - TUNEL for apoptosis
- In situ hybridization (ISH)
  - mRNA
  - miRNA
  - Fluorescent In situ hybridization (FISH)

Storage and stability

- Individual slide is put in an air-tight pack with inert gas.
- If the slides are stored at 4C, they are good for up to one year.

How processed

- Tissues were initially fixed with formalin except for some of the animal tissues
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Sectioned by microtome in 4 μm thickness

Before use

- Dry slides for 1 hour in a oven at 60C.
- Dewax slides in xylene for 4 minutes x 5 times.
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes.

Slide orientation

- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area	1	2	3	4	5	6	7	8	9	10
	11	12	13	14	15	16	17	18	19	20
	21	22	23	24	25	26	27	28	29	30
	30	32	33	34	35	36	37	38	39	40
	41	42	43	44	45	46	47	48	49	50
	51	52	53	54	55	56	57	58	59	60

■ Tissue types*

The "tissue type" column in the data sheet denotes the following categories.

1. normal tissue from a non-cancer patient
2. normal tissue from a cancer patient, but the cancer involves unrelated organ
3. normal tissue adjacent to the cancer
4. benign tumor
5. tumor of borderline malignancy or uncertain malignant potential
6. cancer

NBP2-30328 - Human Various Tissue MicroArray (Cancer)

No.	Age	Sex	Organ	Diagnosis	Tissue type*
1	59	M	Skin	malignant melanoma	6
2	25	F	Skin	squamous cell carcinoma	6
3	50	F	Breast	infiltrating duct carcinoma	6
4	26	F	Breast	infiltrating duct carcinoma	6
5	35	F	Breast	infiltrating lobular carcinoma	6
6	57	F	Breast	invasive papillary carcinoma	6
7	40	M	Lymph node	malignant lymphoma, immunoblastic	6
8	53	F	Bone	osteosarcoma, fibroblastic type	6
9	26	M	Bone	giant cell tumor	5
10	28	M	Bone	chondrosarcoma, well differentiated	6
11	51	F	Soft tissue	liposarcoma, mixed round cell and myxoid type	6
12	55	F	Soft tissue	leiomyosarcoma, metastasis to lung	6
13	52	F	Nasal cavity	undifferentiated carcinoma	6
14	60	M	Lung	adenocarcinoma, moderately differentiated	6
15	51	F	Lung	squamous cell carcinoma, poorly differentiated	6
16	56	M	Lung	mucinous adenocarcinoma	6
17	57	M	Lung	squamous cell carcinoma, metastasis to soft tissue	6
18	61	M	Tongue	squamous cell carcinoma, well differentiated	6
19	65	M	Liver	cholangiocarcinoma, poorly differentiated	6
20	64	M	Liver	hepatocellular carcinoma, moderately differentiated	6
21	45	M	Liver	hepatocellular carcinoma, poorly differentiated	6
22	42	F	Liver	leiomyosarcoma, metastasis to abdominal wall	6
23	71	M	Gallbladder	adenocarcinoma, moderately differentiated	6
24	71	M	Pancreas	adenocarcinoma, moderately differentiated	6
25	69	M	Esophagus	squamous cell carcinoma, well differentiated	6
26	73	M	Stomach	adenocarcinoma, poorly differentiated	6
27	63	M	Stomach	adenocarcinoma, moderately differentiated	6
28	51	F	Stomach	adenocarcinoma, poorly differentiated	6
29	29	M	Stomach	adenocarcinoma, poorly differentiated, metastasis to lymph node	6
30	51	M	Stomach	adenocarcinoma, poorly differentiated, metastasis to liver	6
31	63	M	Stomach	malignant lymphoma, diffuse large B cell lymphoma	6
32	51	M	Stomach	gastrointestinal stromal tumor, high risk	5
33	42	M	Small intestine	gastrointestinal stromal tumor, malignant	6
34	52	F	Appendix	mucinous adenocarcinoma (pseudomyxoma peritonei)	6
35	68	M	Colon	adenocarcinoma, moderately differentiated	6
36	44	M	Colon	mucinous carcinoma	6
37	82	M	Rectum	adenocarcinoma, moderately differentiated	6
38	66	M	Rectum	adenocarcinoma, moderately differentiated	6
39	75	F	Kidney	transitional cell carcinoma, moderately differentiated	6
40	53	M	Kidney	renal cell carcinoma, clear cell type	6
41	48	M	Kidney	renal cell carcinoma, chromophobe type	6
42	65	M	Urinary bladder	transitional cell carcinoma, poorly differentiated	6
43	78	M	Urinary bladder	transitional cell carcinoma, poorly differentiated	6
44	76	M	Prostate	adenocarcinoma, Gleason's grade 7/10	6
45	30	M	Testis	seminoma, classic type	6
46	57	F	Uterus	endometrial adenocarcinoma, moderately differentiated	6
47	73	F	Uterus	endometrial adenocarcinoma, moderately differentiated	6
48	46	F	Uterus	leiomyosarcoma, metastasis to soft tissue	6
49	63	F	Uterine cervix	squamous cell carcinoma	6
50	58	F	Ovary	clear cell adenocarcinoma	6
51	35	F	Ovary	endometrioid carcinoma, well differentiated	6
52	15	F	Ovary	mucinous cystadenocarcinoma, well differentiated	6
53	48	F	Ovary	granulosa cell tumor	5
54	67	F	Adrenal gland	cortical carcinoma	6
55	61	F	Adrenal gland	pheochromocytoma	5
56	53	F	Thyroid	papillary carcinoma	6
57	58	F	Thyroid	minimaly invasive follicular carcinoma	6
58	74	M	Thymus	thymoma, cortical type	5
59	62	M	Brain	glioblastoma multiforme	6
60	64	F	Skin	malignant melanoma, metastasis to lymph node	6